Sugar with your protein? - Generation of a fucosylation-deficient CHO cell host to produce therapeutics with enhanced potency

Traditional CHO cell lines naturally produce predominantly fucosylated antibodies, limiting their therapeutic potential. This white paper discusses how targeted fucosyltransferase gene knockout creates a genetically stable platform that consistently produces 100% afucosylated antibodies, addressing critical challenges in oncology and autoimmune therapeutics where enhanced ADCC activity can make the difference between treatment success and failure.

Key advantages for biotherapeutic development:

• Enhanced ADCC potency
• Consistent, reproducible production
• Address genetic polymorphisms
• Robust and genetically-stable technology
• Reduced manufacturing complexity and costs

Download the white paper to learn how to accelerate your path to more effective biotherapeutics.

The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.